Skip to content

Clinical Trials

Clinical Trials

CIRT

CIRT

featureImage
Read full HCC paper here
featureImage
Read full mCRC paper here
featureImage
Watch CIRSE Symposium here


Results from the CIRT study confirm safety and effectiveness of SIRT with Y-90 resin microspheres within the real-world setting and confirm findings from the earlier studies

1027 patients

Results from the mCRC cohort

CIRT Banner before buttons



Patients enrolled


Abbreviations:
HCC: Hepatocellular carcinoma ; mCRC: metastatic colorectal cancer ; ECOG PS: Eastern Cooperative Oncology Group - Performance Status ; APRI: AST to Platelet Ratio Index ; TACE: Transarterial chemoembolization ; BSA : Body surface area ; OS: Overall survival ; PFS: Progression-free survival ; REILD: Radioembolization-Induced Liver Disease

References:

1. Helmberger T et al. Cardiovasc Intervent Radiol 2021; 44: 21–35. 2. Schaefer N et al. Clin Colorectal Cancer 2022; doi: 10.1016/j.clcc.2022.09.002. 3. Kolligs et al. JHEP Reports 2022; 5:100633. doi: 10.1016/j.jhepr.2022.100633

Indications for Use: SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intrahepatic artery chemotherapy (IHAC) of FUDR (Floxuridine). Consult the Instructions for Use for a complete listing of indications, contraindications, side effects, warnings, and precautions.